To include your compound in the COVID-19 Resource Center, submit it here.

Management tracks: OncoMed, Neurocrine

Cancer company OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Chairman, President and CEO Paul Hastings has resigned. The company is seeking a replacement. Perry Karsen will serve as chairman. Hastings began a medical leave of absence on Sept.

Read the full 367 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers